A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
← catalyst calendarNCT06848088 · readout in 1,148 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Non randomized · None · Other
Enrollment
48estimated
Sites
11
Countries
Ireland, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-14 | actual | When the study began enrolling |
| Primary completion | 2029-10-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-10 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Melanoma
Intervention
- Drug: Fianlimab+cemiplimab — also filed as REGN3767, REGN2810, Libtayo®
Primary outcome
what the primary-completion date above is the date OFDeath from any cause starting at time of initial treatment with fianlimab and cemiplimab in study R3767-ONC-1613
measured Up to 4 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed